P02.08 Immune-related protein changes due to standard of care therapy in recurrent ovarian cancer patients

• T Baert,
• J Ceusters,
• G Thirion,
• A Coosemans,
• S Claes,
• J Kempeneers,
• D Schols

Affiliations

T Baert

5Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium

J Ceusters

1Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium

G Thirion

1Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium

A Coosemans

1Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium

S Claes

3Department of Orthopedics and Traumatology, University Hospitals Leuven, Campus Pellenberg, Leuven, Belgium

J Kempeneers

1Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium

D Schols

3Department of Microbiology, Laboratory of Virology and Chemotherapy (Rega Institute), Immunology and Transplantation, KU Leuven, Leuven, Belgium